What happens if you stop Foundayo or Zepbound?

Zepbound's label includes a trial that stopped the drug on purpose; Foundayo's does not, which is a difference in what is known rather than in what happens. On Zepbound's label, the people randomly assigned to stop gained 14% of body weight over the following 12 months while those who carried on lost 5.5% more. That figure belongs to Zepbound's trial, so this page does not apply it to Foundayo.

Is Foundayo or Zepbound better for weight loss?

Foundayo reports 11.1% average weight loss and Zepbound 20.9%, each from its own trial. The two were not compared against each other, so the higher figure is not a result of a head-to-head and this page does not present it as one. What is comparable is what each costs, below.

Which is cheaper, Foundayo or Zepbound?

Foundayo, at $299 a month against $449 — a difference of $150 a month, or $2,249 over a year counting 12 fills a year for Foundayo and 13 for Zepbound. Both figures are the maintenance price rather than an introductory rate.

Can you switch between Foundayo and Zepbound?

They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.

← All providers and medications

Foundayo (orforglipron) vs Zepbound (tirzepatide)

Verdict

Foundayo comes out ahead on this table, winning on entry price. Zepbound scores higher on the published halfrx formula, 7.3 against 6.3; the formula takes in more than this table does.

Computed from the stored fields, so it moves when a price does. Nothing here is written by hand or by a model.

Which is cheaper, Foundayo (orforglipron) or Zepbound (tirzepatide)?

Foundayo (orforglipron) is $149–$349 a month all-in, read from its own page on 2026-09-12; Zepbound (tirzepatide) is $299–$699, read from its own page on 2026-08-19. At the maintenance dose the gap is $150 a month, which is $2,249 across a year, counting 12 fills for Foundayo (orforglipron) and 13 for Zepbound (tirzepatide). Trial weight loss was 11.1% against 20.9%, from separate trials with different populations, so the gap is not a measured difference between the two. Every axis below is computed from stored fields rather than written by hand, so the comparison moves when a price does. They were last checked on 2026-09-12 and 2026-08-19. Neither carries an FTC action, a state action, a BBB F grade or an FDA warning letter. The published formula scores them 6.3 and 7.3 out of 10, arithmetic over the same stored fields rather than an editor's preference.

Head to head

Foundayo (orforglipron) against Zepbound (tirzepatide), one row per axis, with the side that wins each axis marked.
What decides it	Foundayo $149–$349/mo	Zepbound $299–$699/mo
Entry priceFoundayo (orforglipron) is $150/mo cheaper to start — $149 against $299.	✓ better here	—
Regulatory and complaint riskNeither carries a lawsuit, an FDA warning letter or a supply-risk flag.	tied	tied
Average weight loss in trialsFoundayo (orforglipron) reports 11.1% and Zepbound (tirzepatide) 20.9%, each from its own trial. They were not compared against each other, and the populations, durations and endpoints differ, so the higher number is not a better result — it is a different study.	not comparable	not comparable

What the trials, the titration and a year actually say

Axis	Foundayo	Zepbound
Mean weight loss in the cited trial	11.1%	20.9%
The trial that figure comes from	ATTAIN-1, Trial 1 on the label, 72 weeks: 11.1% mean weight loss at 17.2 mg against 2.1% on placebo, intention-to-treat.	SURMOUNT-1, Study 1 on the label, 72 weeks: 20.9% mean weight loss at 15 mg against 3.1% on placebo, intention-to-treat.
Maintenance dose	5.5 mg, 9 mg, 14.5 mg or 17.2 mg daily	5 mg, 10 mg or 15 mg once weekly
Earliest week you reach it	week 9	week 5
Year one at the published price of every step	$3,188	$5,637

Trial percentages are quoted from the label or the named trial beside them. They are not a head-to-head result: different populations, different durations, different endpoints. That is why the comparison above scores this axis as not comparable rather than awarding it to the higher number. The year-one figures walk each titration step at its published price and count the fills each manufacturer bills a year: 12 for Foundayo, 13 for Zepbound. The full arithmetic is published.

Go to Foundayo ↗Go to Zepbound ↗

Read the price gap carefully: these two are not the same purchase

These are different molecules — orforglipron against tirzepatide — so this is a comparison of two treatments, not of two prices for one.
Against every medication on this site with a verified maintenance price, Foundayo (orforglipron) is the 3rd cheapest of 9 and Zepbound (tirzepatide) the 8th — the cheapest of them all is $75.

Eli Lilly

Foundayo (orforglipron)

6.3

$149–$349/mo all-in

verified 2026-09-12

Newly approvedPrice conditional on refill timingBoxed warning

Eli Lilly

Zepbound (tirzepatide)

7.3

$299–$699/mo all-in

verified 2026-08-19

Price conditional on refill timingBoxed warning

Foundayo (orforglipron)

Pros

+A daily pill with no injection, no needles and no refrigeration — unlike semaglutide pills it is a small molecule, so there are no food-and-water timing rules to follow.[3]
+$149 a month at the entry dose through LillyDirect — the lowest self-pay price for a branded GLP-1 on this site, matched only by the Wegovy pill's first month.[4]
+11.1% mean weight loss over 72 weeks in ATTAIN-1, intention-to-treat — below the Wegovy tablet's 13.6%, and well above the older oral options.[2]
+Being a small molecule, it is manufactured chemically rather than biologically — supply scales in a way peptide injectables cannot.[3]
+Commercially insured with coverage, Lilly's card can bring it to as little as $25 a month.[1]

Cons

−Approved 1 April 2026, so real-world safety data outside trials is still thin compared with semaglutide's years of use.[2]
−$649 list price if you have no coverage and do not use the LillyDirect self-pay channel.[4]
−Weight loss trails tirzepatide injection, which reaches roughly 20%+ in its pivotal trials.[2]
−Maintenance doses hold their $299 price only while you refill within 45 days; lapse and they are $349.[1]

Sources

Zepbound (tirzepatide)

Pros

+Highest average weight loss of any approved medication — around 20.9% at the 15 mg dose in SURMOUNT-1.[2]
+Dual GIP/GLP-1 agonist, a different mechanism from semaglutide, so it often works for people semaglutide failed.[2]
+$299/mo at the starting dose direct from Lilly against a $1,086 list price, with home delivery of vials or pens at the same price.[1]
+Also approved for obstructive sleep apnea, which can unlock insurance coverage that a weight indication alone would not.[2]
+If you are commercially insured with coverage, Lilly's card can bring it to as little as $25 a month.[1]

Cons

−Weekly injection with the usual GI side effects — nausea, vomiting, diarrhea and constipation are the common discontinuation reasons.[2]
−The advertised $449 ceiling is conditional. It holds only while you refill within 45 days; lapse once and 10 mg and above cost $699 — 56% more than the number in the advert.[1]
−Lilly defines a month as 28 days, so a year is 13 fills, not 12. At $449 that is $5,837 a year against the $5,388 that 'per month' implies — $449 of hidden annual cost.[1]
−$1,086 list price if you have no coverage and do not use LillyDirect self-pay.[1]
−Weight regain after stopping is the documented norm, so the cost is ongoing rather than a course.[2]
−2.5 mg is a starting dose and is not approved for maintenance, so the $299 headline is a price nobody stays on.[1]

Sources

Foundayo side effects →Zepbound side effects →Foundayo dosage →Zepbound dosage →

Comparisons are computed from the fields on each card, not written by hand or by a model, so they change when the data does. Information only, not medical advice. halfrx may earn a commission from some links, which never changes what a comparison says.

Everything on Foundayo

Everything on Zepbound

Foundayo against Zepbound, answered

What happens if you stop Foundayo or Zepbound?: Zepbound's label includes a trial that stopped the drug on purpose; Foundayo's does not, which is a difference in what is known rather than in what happens. On Zepbound's label, the people randomly assigned to stop gained 14% of body weight over the following 12 months while those who carried on lost 5.5% more. That figure belongs to Zepbound's trial, so this page does not apply it to Foundayo.
Is Foundayo or Zepbound better for weight loss?: Foundayo reports 11.1% average weight loss and Zepbound 20.9%, each from its own trial. The two were not compared against each other, so the higher figure is not a result of a head-to-head and this page does not present it as one. What is comparable is what each costs, below.
Which is cheaper, Foundayo or Zepbound?: Foundayo, at $299 a month against $449 — a difference of $150 a month, or $2,249 over a year counting 12 fills a year for Foundayo and 13 for Zepbound. Both figures are the maintenance price rather than an introductory rate.
Can you switch between Foundayo and Zepbound?: They are different molecules, so this is a change of medication rather than of brand, and the one you move to is started on its own dosing schedule.